Boehringer awarded FDA Commissioner's National Priority Voucher for HERNEXEOS® in HER2 lung cancer

RIDGEFIELD, Conn., Nov. 7, 2025 /PRNewswire/ -- The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets), currently under investigation for first-line use in treatment-naïve patients with HER2...